ArticleInvestigative ophthalmology & visual science2026
CD14+CD56+ Cell Is an Independent Regulatory Monocyte Subpopulation Increased in VKHS Patients Following Glucocorticoids Therapy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Vogt-Koyanagi-Harada syndrome (VKHS) has been established as an autoimmune disease targeting melanocytes; however, its underlying mechanism remains obscure. We previously found an increased proportion of CD14+CD56+ monocyte (CD56+ monocyte thereafter) accompanied by decreased T cell frequency in the peripheral blood of patients with VKHS treated with glucocorticoids (GCs), suggesting the immunoregulatory function of this monocyte. However, whether CD56+ monocyte is a bona fide regulatory monocyte subset in VKHS is to be determined. Methods and Results: Through morphological, transcriptomic, and immunophenotypic analyses, we confirm that CD56+ monocyte constitutes a distinct immunoregulatory monocyte subset compared with CD56- monocyte and NK cell. Upon lipopolysaccharide (LPS) stimulation, CD56+ monocytes showed greater capacity to secrete pro-inflammatory cytokines (TNF-α, IL-23, IL-8, and IL-6) and anti-inflammatory cytokine IL-10 compared with CD56- monocytes and NK cells. Interestingly, secretion of granzyme B and perforin is observed in CD56+ monocytes but not CD56- monocytes in steady-state conditions, albeit at lower levels than NK cells. Moreover, CD56+ monocytes demonstrate superior phagocytosis, antigen processing, and migration abilities but intermediate adhesion capabilities compared with CD56- monocytes and NK cells. Importantly, monocytes treated in vitro and derived from GC-treated patients with VKHS harbor an increased proportion of CD56+ monocytes, and exhibit enhanced migration and reduced adhesion, along with stronger capacity to inhibit CD4+ T cell proliferation. Conclusions: These findings highlight the importance of CD56+ monocytes, as an independent regulatory monocyte subset, in response to GC therapy in the context of acute VKHS. The potential mechanism revealed in this study will provide insight into novel treatment strategies of VKHS by harnessing CD56+ monocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.